FeesSafety
Pluang+

Tempus AI shows stronger growth outlook than Grail in healthcare tech race for 2027.

Market News
19 Nov 2026, 19:13 WIB
The Motley Fool
View Source
Neutral
Tempus AI shows stronger growth outlook than Grail in healthcare tech race for 2027.

Tempus AI and Grail are two leading healthcare tech stocks focused on genomics and cancer detection. Tempus AI, with a $12 billion market cap, reported $1.28 billion revenue in 2025, growing 83%, and expects 25% annual growth, driven by AI-powered precision medicine and partnerships. Grail, valued at $4.6 billion, specializes in early cancer detection with its Galleri test but faces regulatory hurdles after a failed NHS trial; it posted $147.2 million revenue in 2025, up 17.2%. Tempus AI's broader data platform and clearer growth path make it a more promising investment for 2027 despite higher debt and losses.

As investors weigh the prospects of Tempus AI and Grail for 2027, Tempus AI shares are currently priced at USD 60.80 on Pluang, down 4.43% in the past day as of Nov 20, 2026 00:21 WIB. The stock holds a market cap of $11.60 billion on Pluang, close to its reported valuation, with a 52-week trading range between $41.55 and $85.08. Pluang users show strong buying interest, with 95% of order activity on the platform being buys and a typical holding period of 25 days.

More News (TEM)

banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App